Timothy Spelman

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

Tim Spelman, Melinda Magyari, Fredrik Piehl, Anders Svenningsson, Peter Vestergaard Rasmussen, Matthias Kant, Finn Sellebjerg, Hanna Joensen, Jan Hillert, Jan Lycke

Journal article  |  2021  |  JAMA Neurol

Importance: Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary markedly between Denmark and Sweden. The d..

010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort

Helmut Butzkueven, Tim Spelman, Tomas Kalincik, Katherine Buzzard, Anneke Van der Walt, Jeanette Lechner-Scott, Suzanne Hodgkinson, Ernest Butler, Richard Macdonell, Mark Slee, MSBase Study Group, Bruno Marcel

Conference Proceedings  |  2021  |  Oral abstracts

The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city

Nick Scott, Allan Saul, Tim Spelman, Mark Stoove, Alisa Pedrana, Alexander Saeri, Emily Grundy, Liam Smith, Michael Toole, Chandini Raina McIntyre, Brendan S Crabb, Margaret Hellard

Journal article  |  2021  |  PLOS ONE

BACKGROUND: Whilst evidence of use of face masks in reducing COVID-19 cases is increasing, the impact of mandatory use across a la..

Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry

Tim Spelman, Lars Forsberg, Kyla McKay, Anna Glaser, Jan Hillert

Journal article  |  2021  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: The primary objective of this study was to analyse the association between multiple sclerosis (MS) disease-modifying t..

Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.

Stelliana Goutzamanis, Timothy Spelman, Brendan Harney, Paul Dietze, Mark Stoove, Peter Higgs, Alexander Thompson, Joseph S Doyle, Margaret Hellard

Journal article  |  2021  |  J Viral Hepat

The impact of hepatitis C cure with direct-acting antivirals (DAAs) on patient-reported outcomes (PROs) in community settings rema..

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry

Jan Hillert, Jon A Tsai, Mona Nouhi, Anna Glaser, Tim Spelman

Journal article  |  2021  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Teriflunomide and dimethyl fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with simi..

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry

Helmut Butzkueven, Tim Spelman, Dana Horakova, Stella Hughes, Claudio Solaro, Guillermo Izquierdo, Eva Kubala Havrdova, Francois Grand'Maison, Alexandre Prat, Marc Girard, Raymond Hupperts, Marco Onofrj, Alessandra Lugaresi, Bruce Taylor, Gavin Giovannoni, Ludwig Kappos, Stephen L Hauser, Xavier Montalban, Licinio Craveiro, Rita Freitas, et al.

Journal article  |  2021  |  EUROPEAN JOURNAL OF NEUROLOGY

BACKGROUND AND PURPOSE: Reaching Expanded Disability Status Scale (EDSS) ≥7.0 represents the requirement for a wheelchair. Here we..

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

Pietro Iaffaldano, Giuseppe Lucisano, Helmut Butzkueven, Jan Hillert, Robert Hyde, Nils Koch-Henriksen, Melinda Magyari, Fabio Pellegrini, Tim Spelman, Per Soelberg Sorensen, Sandra Vukusic, Maria Trojano

Journal article  |  2021  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: The optimal timing of treatment starts for achieving the best control on the long-term disability accumulation in mult..

Amélioration ou maintien du statut en matière d’emploi chez les patients atteints de sclérose en plaques rémittente-récurrente (SEP RR) traités par natalizumab dans le cadre l’étude observationnelle TYSABRI TOP

Gisela Kobelt, Maria Trojano, Tim Spelman, Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, Shirley Liao, Carlos Acosta, Pei-Ran Ho, Stephanie Licata

Journal article  |  2021  |  Revue Neurologique

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study.

Thomas A Rasmussen, Lakshmi Rajdev, Ajantha Rhodes, Ashanti Dantanarayana, Surekha Tennakoon, Socheata Chea, Tim Spelman, Shelly Lensing, Rachel Rutishauser, Sonia Bakkour, Michael Busch, Janet D Siliciano, Robert F Siliciano, Mark H Einstein, Dirk P Dittmer, Elizabeth Chiao, Steven Deeks, Christine Durand, Sharon R Lewin

Journal article  |  2021  |  Clin Infect Dis

BACKGROUND: Antibodies to PD-1 and CTLA-4 may perturb HIV persistence during antiretroviral therapy (ART) by reversing HIV-latency..